Merck's new injectable cancer drug, Keytruda Qlex, promises to transform patient treatment with a quick administration time and flexible dosing, all while maintaining effectiveness. Available in late September, this shift is critical as the market braces for biosimilar competition.
A groundbreaking study reveals that combining Trodelvy and Keytruda reduces tumor progression risk by over a third in aggressive breast cancer cases, paving the way for new treatment options.
